FRM
NBIX icon

Fox Run Management’s Neurocrine Biosciences NBIX Stock Holding History

Fox Run Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,793
Closed -$746K – 1177
2026
Q1 		$746K Sell
5,793
-5,527
-49% -$733K 0.13% 268
2025
Q4 		$1.61M Buy
11,320
+1,433
+14% +$208K 0.25% 60
2025
Q3 		$1.39M Buy
+9,887
New +$1.34M 0.22% 108
2025
Q2 		– Sell
-7,482
Closed -$828K – 1096
2025
Q1 		$828K Buy
+7,482
New +$948K 0.13% 268
2024
Q4 		– Sell
-6,824
Closed -$786K – 1069
2024
Q3 		$786K Buy
+6,824
New +$936K 0.18% 201
2024
Q2 		– Sell
-3,694
Closed -$509K – 969
2024
Q1 		$509K Buy
+3,694
New +$504K 0.11% 364
2022
Q3 		– Sell
-5,961
Closed -$581K – 756
2022
Q2 		$581K Buy
+5,961
New +$550K 0.29% 89
2022
Q1 		– Sell
-3,858
Closed -$329K – 633
2021
Q4 		$329K Buy
+3,858
New +$355K 0.19% 200
2021
Q3 		– Sell
-3,025
Closed -$294K – 571
2021
Q2 		$294K Buy
+3,025
New +$290K 0.27% 171
2020
Q4 		– Sell
-2,859
Closed -$275K – 251
2020
Q3 		$275K Sell
2,859
-79
-3% -$9.14K 0.69% 55
2020
Q2 		$358K Buy
+2,938
New +$325K 0.47% 69
2019
Q4 		– Sell
-3,111
Closed -$280K – 478
2019
Q3 		$280K Sell
3,111
-1,479
-32% -$138K 0.25% 179
2019
Q2 		$388K Buy
+4,590
New +$377K 0.26% 137
2019
Q1 		– Sell
-5,021
Closed -$359K – 618
2018
Q4 		$359K Buy
5,021
+3,120
+164% +$299K 0.19% 211
2018
Q3 		$234K Buy
+1,901
New +$216K 0.1% 432
2017
Q2 		– Sell
-8,300
Closed -$359K – 757
2017
Q1 		$359K Sell
8,300
-16,500
-67% -$707K 0.15% 302
2016
Q4 		$960K Buy
24,800
+20,500
+477% +$928K 0.5% 10
2016
Q3 		$218K Buy
+4,300
New +$214K 0.13% 373

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fox Run Management's NBIX Position: Q2 2026 in Review

Fox Run Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 5,793 shares — an estimated $746K sold.

Fox Run Management first reported a position in NBIX in Q3 2016 and held it in 18 quarters. The position peaked at $1.61M in Q4 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Fox Run Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 5,793 Neurocrine Biosciences shares in Q2 2026, an estimated $746K.
  • Fox Run Management first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 18 quarters.
  • Fox Run Management's Neurocrine Biosciences position peaked at $1.61M in Q4 2025.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.